CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
  
  OVERVIEW OF ACTIVITY
  The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many different tumor types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided medical oncologists and patients with many additional and beneficial FDA-endorsed treatment options. Although this dynamic appears to be prevalent in many corners of oncology, scientific and clinical advancements in the treatment of breast cancer have made it particularly pronounced in this area.
  
  To bridge the gap between research and patient care, this video presentation by Dr Joyce O’Shaughnessy uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of breast cancer with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Review emerging research data evaluating the use of anti-HER2 therapies to reduce the residual risk of relapse for patients with localized HER2-positive breast cancer receiving adjuvant trastuzumab/chemotherapy.
  • Develop an understanding of the mechanism of action of, available Phase III data with and current role of recently approved CDK4/6 inhibitors for the management of advanced ER-positive breast cancer.
  • Recall available efficacy and safety data with PARP inhibitors in patients with BRCA mutation-positive, HER2-negative metastatic breast cancer, and consider the diagnostic and therapeutic implications of these findings for clinical care.
  • Appraise the rationale for and clinical data with investigational anti-PD-1/PD-L1 antibodies for patients with metastatic breast cancer, and use this understanding to prioritize clinical trial opportunities for appropriate individuals eligible for participation.
  • Identify ongoing trials of other investigational approaches in breast cancer, and refer patients and obtain consent for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  Joyce O’Shaughnessy, MD
  Chair, Breast Cancer Research Program
  Baylor Charles A Sammons Cancer Center
  Celebrating Women Chair in Breast Cancer Research
  Texas Oncology
  US Oncology
  Dallas, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genomic Health Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme; Contracted Research: Takeda Oncology.
  
  Project Steering Committee
  
  Kimberly L Blackwell, MD
  Professor of Medicine
  Director, Breast Cancer Program
  Duke Cancer Institute
  Durham, North Carolina
  
  Advisory Committee: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Eisai Inc, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Pierian Biosciences, Syndax Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Coherus Biosciences, G1 Therapeutics, Genentech, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sandoz; Contracted Research: Celgene Corporation, Genentech, Novartis, Pfizer Inc.
  
  Harold J Burstein, MD, PhD
  Associate Professor of Medicine
  Harvard Medical School
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  William J Gradishar, MD
  Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
  Deputy Director, Clinical Network
  Robert H Lurie Comprehensive Cancer Center of Northwestern University
  Director, Maggie Daley Center for Women’s Cancer Care
  Interim Chief, Division of Hematology/Oncology
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  No relevant conflicts of interest to disclose.
  
  Sara A Hurvitz, MD
  Associate Professor of Medicine
  Director, Breast Oncology Program, Division of Hematology/Oncology
  University of California, Los Angeles
  Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
  Los Angeles, California
  Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
  Santa Monica, California
  
  Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, BioMarin Pharmaceutical Inc, Boehringer Ingelheim Pharmaceuticals Inc, Cascadian Therapeutics, Dignitana AB, Genentech, GlaxoSmithKline, Lilly, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; Paid Travel: Bayer HealthCare Pharmaceuticals, Lilly, Novartis, OBI Pharma Inc.
  
  Ruth M O’Regan, MD
  Professor of Medicine
  Chief, Division of Hematology/Oncology
  University of Wisconsin Carbone Cancer Center
  Madison, Wisconsin
  
  Advisory Committee: Genentech, Genomic Health Inc, Lilly, Novartis, Pfizer Inc; Contracted Research: Eisai Inc, Novartis, Pfizer Inc.
  
  Mark D Pegram, MD
  Susy Yuan-Huey Hung Professor of Medicine
  Director of the Breast Oncology Program
  Associate Dean, Clinical Research Quality
  Associate Director for Clinical Research
  Stanford Cancer Institute
  Stanford University School of Medicine
  Stanford, California
  
  Advisory Committee and Consulting Agreements: Amgen Inc, Genentech, Novartis, Pfizer Inc, Roche Laboratories Inc.
  
  Joseph A Sparano, MD
  Professor of Medicine and Women’s Health
  Albert Einstein College of Medicine
  Associate Chairman, Department of Oncology
  Montefiore Medical Center
  Bronx, New York
  
  Consulting Agreements: Genentech, Lilly, Pfizer Inc; Contracted Research: Atossa Genetics Inc, Deciphera Pharmaceuticals LLC, Genentech, GlaxoSmithKline, Merck, Novartis, Prescient Therapeutics Pty Ltd, Takeda Oncology; Ownership Interest: MetaStat Inc.
  
  PROJECT CHAIR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Lilly and Tesaro Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: June 2018
  Expiration date: June 2019